The FDA’s delay in approving MDMA-assisted therapy for PTSD has created uncertainty in the field of psychedelic medicines. Despite this setback, experts at the HLTH 2024 conference in Las Vegas remain hopeful for the future of this treatment option. Lykos Therapeutics had submitted a new drug application for MDMA-assisted therapy, but the FDA requested an additional Phase 3 trial due to concerns raised by an advisory committee. Efforts are also being made at the state level to advance psychedelic-assisted therapy, such as Arizona appropriating funds for psilocybin research. Approvals by the FDA and insurance coverage are still needed for wider access to these treatments.
Source link
What’s Next for Psychedelic Medicines?
